Efficacy and Safety of UGN-101 in Recurrent Patients
Status:
Withdrawn
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate the efficacy and safety of UGN-101 administered to the
upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a
complete response (CR) at the Primary Disease Evaluation (PDE) 1 Visit and are subsequently
found to have a documented recurrence of low grade (LG) upper tract urothelial carcinoma
(UTUC) at follow up (FU).